Glenmark Pharmaceuticals: Crofelemer - limited near-term opportunity
` Arbitration panel rules in Glenmark's favor in Crofelemer litigation
` Crofelemer may have limited commercial opportunity; Revamilast in RA
remains the focus
link
http://www.kotaksecurities.com/pdf/indiadaily/indiadaily24082012yu.pdf
No comments:
Post a Comment